Navigation Links
Enzyme to Boost Effect of Tumor Vaccine

The effects of tumor vaccines seem to get boosted by a 'super' form of an enzyme called Akt1. This enzyme is expected //to help extend the life of dendritic cells. These cells are also referred to as the main switch of the immune system that improves the way the T-cells respond to attack a tumor. This was divulged in a report that appears in an electronic media, online in the latest issue of the journal Nature Biotechnology. Researchers from Baylor College of Medicine conducted the study.

The desirable immune response is achieved by maintaining the window of activation longer. This is possible by keeping dendritic cells alive for longer time explained Dr. David Spencer, associate professor of immunology at BCM. 'The longer your dendritic cells are alive and active, the more likely you are to expand the appropriate T-helper repertoire and ultimately the desirable cytotoxic (cell killing) T-lymphocytes.'

'The dendritic cells are the master switch in the immune system. They decide whether there will be a robust immune response or a tempered immune response to pathogens or cancer,' he said. Using a variety of sophisticated laboratory techniques, Spencer and his colleagues found that Akt1 'was in fact essential for dendritic cell survival,' he said. Then they sought to develop a more potent form of Akt1 that would enable the dendritic cells to live longer, boosting immune response.

To do that, they altered the enzyme so that it targeted a particular domain on the plasma membrane of the cell where signaling occurred, making the action of Akt1 more specific. They then eliminated a small part of the Akt1 molecule that had a negative or inhibitory effect. 'It turned out that the altered molecule was much more potent,' Spencer said. He credited graduate student Dongsu Park with doing much of the work to develop the super form of Akt1.

Using specially designed adenoviruses, he and his colleagues put the modified 'super' Akt1 molec ule into the dendritic cells. 'As predicted, these dendritic cells lived longer and were more potent, both in the laboratory and in mice,' he said. 'It led to the elimination of some very aggressive tumors in the mice.'

In the laboratory, they found that the 'super' Akt1 also has a potent effect on human dendritic cells as well, although it has not been used to treat people yet. He expects that when the enzyme is used in people, the first target will be prostate cancer – a long-standing interest of his laboratory. However, he said, it could be modified to attack other tumors as well.


Related medicine news :

1. Enzyme may be target for obesity drugs
2. Researchers trick Alzheimers Enzyme
3. Enzyme stimulates growth of adult stem cells
4. Enzyme may aid hold back disease
5. Enzyme help destroy cancer cell
6. Enzyme Associated with Memory
7. Enzyme Associated With Memory
8. Brain Enzyme Found To Regulate Weight
9. New Enzyme Identified For Arthritis
10. Enzyme for treatment of arthritis
11. An Enzyme That Turns a One –time Experience into a long-time Memor
Post Your Comments:

(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, ... work on several important health care topics including advance care planning, healthcare costs ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... ... the United States, named Dr. Sesan Ogunleye, as the Medical Director of its new ... the facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, ...
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of indulgence ... high can result in disappointment, perhaps even self-loathing. However, those who set the bar ... from reveals that behind the tendency to set low expectations is ...
(Date:6/24/2016)... ... 2016 , ... Marcy was in a crisis. Her son James, eight, was out of control. ... and physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. ... rocks at my other children and say he was going to kill them. If ...
(Date:6/24/2016)... Diego, CA (PRWEB) , ... June 24, 2016 , ... ... with the American Cancer Society and the Road To Recovery® program to drive cancer ... to seniors and other adults to ensure the highest quality of life and ongoing ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... of Australia,s successful biotechnology scientists, Dr ... company, Noxopharm Limited [ABN 50 608 966 123] ("Noxopharm"). Noxopharm is ... the ASX. Noxopharm is a clinic-ready company with its ... clinical study later this year. ... facing cancer patients - the ability of cancers to become resistant ...
(Date:6/26/2016)... Jazz Pharmaceuticals plc (Nasdaq: JAZZ ... Antitrust Improvements Act of 1976, as amended ("HSR"), with ... ("Celator"; Nasdaq: CPXX ) expired effective June ... As previously announced on May 31, 2016, Jazz ... under which Jazz Pharmaceuticals has commenced a tender offer ...
(Date:6/26/2016)... OTTAWA, Ontario , June 27, 2016  VMS ... the Company,s Board will take whatever measures required to ... the Company,s stock which is currently listed on the ... S Wexler, Company Chairman and CEO, "We are seeing ... be difficult to understand, not only by the Company, ...
Breaking Medicine Technology: